High-dose Fluconazole in Combination with Amphotericin B is More Efficient Than Monotherapy in Murine Model of Cryptococcosis

Overview

Journal Sci Rep

Specialty Science

Date 2017 Jul 7

PMID 28680034

Citations 7

Authors

Julliana Ribeiro Alves Santos

Noelly Queiroz Ribeiro

Rafael Wesley Bastos

Rodrigo Assuncao Holanda

Leticia Chagas Silva

Estela Rezende Queiroz

Daniel Assis Santos

Affiliations

Soon will be listed here.

Abstract

Cryptococcus spp., the causative agents of cryptococcosis, are responsible for deaths of hundreds of thousands of people every year worldwide. The drawbacks of available therapeutic options are aggravated by the increased resistance of yeast to the drugs, resulting in inefficient therapy. Also, the antifungal 5FC is not available in many countries. Therefore, a combination of antifungal drugs may be an interesting option, but in vitro and theoretical data point to the possible antagonism between the main antifungals used to treat cryptococcosis, i.e., fluconazole (FLC), and amphotericin B (AMB). Therefore, in vivo studies are necessary to test the above hypothesis. In this study, the efficacy of FLC and AMB at controlling C. gattii infection was evaluated in a murine model of cryptococcosis caused by C. gattii. The infected mice were treated with FLC + AMB combinations and showed a significant improvement in survival as well as reduced morbidity, reduced lung fungal burden, and the absence of yeast in the brain when FLC was used at higher doses, according to the Tukey test and principal component analysis. Altogether, these results indicate that combinatorial optimization of antifungal therapy can be an option for effective control of cryptococcosis.

Citing Articles

The Dynamics of Cell and Transcriptional Remodeling during Infection.

Freitas G, Gouveia-Eufrasio L, Emidio E, Carneiro H, de Matos Baltazar L, Costa M Cells. 2022; 11(23).

PMID: 36497155 PMC: 9740611. DOI: 10.3390/cells11233896.

A clinical, aetiological, and public health perspective on central nervous system infections in Bolivia, 2017-2018.

Saba Villarroel P, Castro Soto M, Melendres Flores O, Peralta Landivar A, Calderon M, Loayza R Sci Rep. 2021; 11(1):23235.

PMID: 34853372 PMC: 8636643. DOI: 10.1038/s41598-021-02592-6.

Randomized, phase 1/2, double-blind pioglitazone repositioning trial combined with antifungals for the treatment of cryptococcal meningitis - PIO study.

Gouveia-Eufrasio L, Ribeiro N, Santos J, da Costa M, Peres Emidio E, de Freitas G Contemp Clin Trials Commun. 2021; 22:100745.

PMID: 33997457 PMC: 8099743. DOI: 10.1016/j.conctc.2021.100745.

The Added Value of Longitudinal Imaging for Preclinical Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis.

Vanherp L, Poelmans J, Hillen A, Janbon G, Brock M, Lagrou K Antimicrob Agents Chemother. 2020; 64(7).

PMID: 32284382 PMC: 7318040. DOI: 10.1128/AAC.00070-20.

Bioactive Peptides Against Fungal Biofilms.

Oshiro K, Rodrigues G, Monges B, Cardoso M, Franco O Front Microbiol. 2019; 10:2169.

PMID: 31681179 PMC: 6797862. DOI: 10.3389/fmicb.2019.02169.

References

Johnson M, MacDougall C, Ostrosky-Zeichner L, Perfect J, Rex J . Combination antifungal therapy. Antimicrob Agents Chemother. 2004; 48(3):693-715. PMC: 353116. DOI: 10.1128/AAC.48.3.693-715.2004. View

Mukherjee P, Sheehan D, Hitchcock C, Ghannoum M . Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005; 18(1):163-94. PMC: 544182. DOI: 10.1128/CMR.18.1.163-194.2005. View

Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, Helbok R . Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol. 2006; 32(2):177-88. DOI: 10.1111/j.1365-2990.2006.00706.x. View

Sionov E, Chang Y, Garraffo H, Kwon-Chung K . Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother. 2009; 53(7):2804-15. PMC: 2704677. DOI: 10.1128/AAC.00295-09. View

Bicanic T, Muzoora C, Brouwer A, Meintjes G, Longley N, Taseera K . Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009; 49(5):702-9. PMC: 2965403. DOI: 10.1086/604716. View

Varma A, Kwon-Chung K . Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother. 2010; 54(6):2303-11. PMC: 2876399. DOI: 10.1128/AAC.00153-10. View

Durcekova T, Mocak J, Boronova K, Balla J . Effect of the statin therapy on biochemical laboratory tests--a chemometrics study. J Pharm Biomed Anal. 2010; 54(1):141-7. DOI: 10.1016/j.jpba.2010.07.047. View

Kronstad J, Attarian R, Cadieux B, Choi J, DSouza C, Griffiths E . Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat Rev Microbiol. 2011; 9(3):193-203. PMC: 4698337. DOI: 10.1038/nrmicro2522. View

Perfect J . The impact of the host on fungal infections. Am J Med. 2011; 125(1 Suppl):S39-51. DOI: 10.1016/j.amjmed.2011.10.010. View

10.

Santos J, Gouveia L, Taylor E, Resende-Stoianoff M, Pianetti G, Cesar I . Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother. 2012; 56(5):2553-8. PMC: 3346628. DOI: 10.1128/AAC.06098-11. View

11.

Helmy A, Antoniades C, Guilfoyle M, Carpenter K, Hutchinson P . Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS One. 2012; 7(6):e39677. PMC: 3382168. DOI: 10.1371/journal.pone.0039677. View

12.

Day J, Chau T, Wolbers M, Mai P, Dung N, Mai N . Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013; 368(14):1291-1302. PMC: 3978204. DOI: 10.1056/NEJMoa1110404. View

13.

Sudan A, Livermore J, Howard S, Al-Nakeeb Z, Sharp A, Goodwin J . Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother. 2013; 57(6):2793-800. PMC: 3716186. DOI: 10.1128/AAC.00216-13. View

14.

Vidal J, de Oliveira A, Dauar R, Boulware D . Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis. 2013; 17(3):353-62. PMC: 3747670. DOI: 10.1016/j.bjid.2012.10.020. View

15.

Cogliati M . Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An Atlas of the Molecular Types. Scientifica (Cairo). 2013; 2013:675213. PMC: 3820360. DOI: 10.1155/2013/675213. View

16.

Chen S, Meyer W, Sorrell T . Cryptococcus gattii infections. Clin Microbiol Rev. 2014; 27(4):980-1024. PMC: 4187630. DOI: 10.1128/CMR.00126-13. View

17.

Perfect J, Bicanic T . Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol. 2014; 78:49-54. PMC: 4395512. DOI: 10.1016/j.fgb.2014.10.003. View

18.

Santos J, Assuncao Holanda R, Frases S, Bravim M, Araujo G, Campi Santos P . Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis. PLoS One. 2014; 9(11):e112669. PMC: 4231059. DOI: 10.1371/journal.pone.0112669. View

19.

Ianiri G, Idnurm A . Essential gene discovery in the basidiomycete Cryptococcus neoformans for antifungal drug target prioritization. mBio. 2015; 6(2). PMC: 4453551. DOI: 10.1128/mBio.02334-14. View

20.

Ferreira G, Santos J, da Costa M, de Holanda R, Denadai A, de Freitas G . Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii. Antimicrob Agents Chemother. 2015; 59(8):4600-9. PMC: 4505268. DOI: 10.1128/AAC.00466-15. View